Bellerophon Therapeutics Inc (NASDAQ:BLPH)’s stock price fell 19% during mid-day trading on Friday . The company traded as low as $0.31 and last traded at $0.34, 686,800 shares traded hands during mid-day trading. An increase of 177% from the average session volume of 247,847 shares. The stock had previously closed at $0.42.
A number of research firms have issued reports on BLPH. Maxim Group reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Bellerophon Therapeutics in a research note on Thursday, November 7th. ValuEngine downgraded Bellerophon Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 4th.
The stock has a 50 day simple moving average of $0.46 and a 200-day simple moving average of $0.58. The company has a current ratio of 1.96, a quick ratio of 1.96 and a debt-to-equity ratio of 0.25. The firm has a market cap of $28.94 million, a P/E ratio of -1.00 and a beta of -0.05.
In other news, major shareholder Associates Iv L. P. Venrock sold 704,595 shares of the stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $0.50, for a total value of $352,297.50. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Associates Iv L. P. Venrock sold 333,010 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $0.44, for a total value of $146,524.40. The disclosure for this sale can be found here. 53.10% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in BLPH. LPL Financial LLC increased its holdings in shares of Bellerophon Therapeutics by 22.1% in the second quarter. LPL Financial LLC now owns 130,800 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 23,650 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Bellerophon Therapeutics by 8.9% in the second quarter. Renaissance Technologies LLC now owns 1,434,538 shares of the biotechnology company’s stock valued at $860,000 after purchasing an additional 116,862 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Bellerophon Therapeutics by 15.9% in the second quarter. Vanguard Group Inc. now owns 1,152,175 shares of the biotechnology company’s stock valued at $690,000 after purchasing an additional 158,000 shares during the period. 53.36% of the stock is currently owned by institutional investors and hedge funds.
Bellerophon Therapeutics Company Profile (NASDAQ:BLPH)
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.
Featured Story: Using other technical indicators with support levels
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.